ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Vm-MSI: a Vancomycin-Antimicrobial Peptide Conjugate Combating Resistant Bacteria and Broadening the Antimicrobial Spectrum.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enzyme-Flavonoid Synergistic Hydrogel: Enables Glucose-Activated Cascade Acidification and Programmed Drug Release for Diabetic Wound Therapy.Gels (Basel, Switzerland) · 2026Article
- Antimicrobial Peptide Nanoassemblies: Design, Response Mechanisms, and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Vancomycin is a critical last-resort treatment for multidrug-resistant Gram-positive bacteria, particularly severe methicillin-resistant S. aureus (MRSA) infections. However, the rise of vancomycin-resistant strains significantly compromises its therapeutic efficacy. To overcome this challenge, recent research has focused on structural modifications of vancomycin using diverse strategies. Herein, the potential of a modification strategy by coupling vancomycin with antimicrobial peptides (AMPs) that have different mechanisms of action is explored. Among the acquired conjugates, Vm-MSI showed a 20.18 fold improvement in antimicrobial activity over vancomycin and a 1.95 fold increase compared to the parent peptide MSI-78. Vm-MSI not only delays the development of resistance in vancomycin-resistant S. aureus (VRSA) but also exhibits potent activity against a wide range of Gram-negative bacteria. Additionally, Vm-MSI demonstrated strong synergy with several conventional antibiotics of distinct mechanisms and displayed potent activities in eradicating biofilms and persisters. Mechanistic studies revealed the complex antibacterial mechanisms of Vm-MSI, which hinder the development of bacterial resistance. In vivo, Vm-MSI displayed remarkable therapeutic efficacy in mouse models of VRSA-induced skin infection and multidrug-resistant A. baumannii-induced lung infection. These findings underscore the great potential of Vm-MSI as an effective treatment for infections caused by vancomycin-resistant and Gram-negative bacteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.